Biotechnology company specialising in innovative gene therapies
Job no longer available
Biotechnology company specialising in innovative gene therapies
201-500 employees
Job no longer available
201-500 employees
Dedicated to transforming the lives of patients with inherited diseases through innovative gene therapy.
Share this job
11% employee growth in 12 months
Aug 2018
$150m
Dec 2017
$110m
Orchard Technologies is a biotechnology company that specialises in developing gene therapies for serious and life-threatening illnesses. Based in London and Boston, the company went public on the NASDAQ exchange in 2018, reaching a $1b valuation and becoming a unicorn in the process.
In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, endowing the firm with one of the deepest and most advanced gene therapy product candidate pipelines in the industry. Today, the portfolio spans multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
In light of COVID-19, the company had to lay off 25% of its workforce and change tack, instead focusing on more common conditions, including Crohn’s disease, some types of dementia and some neurometabolic disorders. Longer term, there are many challenges for Orchard ahead, the main being to make gene therapy for rare diseases profitable.
Kirsty
Company Specialist at Welcome to the Jungle